Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breat cancers, according to the American Cancer Society. Triple negative breast cancer cells don’t have estrogen or progesterone receptors and also don’t produce much HER2 protein. (The cells test “negative” on all three tests.) These cancers tend to be more common in women younger than 40, who are African-American, or who have a BRCA1 mutation.

Triple-Negative Breast Cancer Clinical Trial

NANT Molecularly Informed Integrated Immunotherapy in Subjects with TNBC Who Have Progressed On or After Standard-of-Care Therapy.

In this trial, treatment will be administered in two phases, an induction and a maintenance phase, as described below. Subjects will continue induction treatment for up to 1 year. Treatment in the study will be discontinued if the subject experiences progressive disease (PD) or unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject’s best interest to continue treatment. Those who have a complete response (CR) in the induction phase will enter the maintenance phase of the study. Subjects who experience ongoing stable disease (SD) or an ongoing partial response (PR) at 1 year may enter the maintenance phase at the Investigator’s discretion.

Subjects may remain on the maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase until the subject experiences PD or unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject’s best interest to continue treatment. The maximum time on study treatment, including both the induction and maintenance phases, is 2 years. (NCT03387085)

Adam M. Brufsky
M.D., Ph.D. Professor of Medicine in the Division of Hematology/Oncology at the University of Pittsburgh, and a member of ImmunityBio’s Scientific Advisory Board
While we have seen long-term declines in death rates for breast cancers, we have yet to find a cure for some of the two million women and men around the world who are diagnosed with this disease every year,” said Adam Brufsky, MD. “Research has shown tremendous potential for getting closer to that cure in immunotherapies that enlist the patient’s immune system to fight cancer.

Recent Research

Recent News

How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious diseases severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Natural killer cell-based immunotherapies are key to future cancer treatments. Our investigational NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.